We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Methylation Profiling for Determining Gene Activity

By Biotechdaily staff writers
Posted on 01 Sep 2004
Researchers working with the plant Arabidopsis have used a powerful new microarray-based methylation profiling technology to study the role of epigenetic information in determining gene activity.

In their study, the investigators at Cold Spring Harbor Laboratory (NY, USA) utilized the MethylScope technology of Orion Genomics (Saint Louis, MO, USA). More...
MethylScope employs a microarray analysis technique to assess to what extent genes in a genome are methylated. The technology relies on proprietary methods to divide genomic DNA into two fractions: methylated and unmethylated.

Each fraction is labeled with a different color of fluorescent dye (e.g., unmethylated DNA is green and methylated DNA is red and is then hybridized to a microarray. If an array feature corresponding to a single gene in the genome glows red, then that gene was methylated in the tissue from which the DNA was prepared. If, however, an array feature glows green, then that gene was unmethylated. Observing the red-green ratio for each feature on an array allows investigators to quantitatively determine the degree to which a gene may be methylated.


The investigators reported in the August 6, 2004, issue of Nature that the DNA sequences at the sites of transposon activity correspond to small interfering RNAs (siRNAs). They also showed that transposable elements could regulate genes epigenetically, but only when inserted within or very close to them.

"Our research concerns the mechanism by which methylated DNA and other epigenetic information determines gene activity,” said senior author Dr. Rob Martienssen, a professor at Cold Spring Harbor Laboratory and co-founder of Orion Genomics. "Because of this ‘second code,' epigenetic changes are emerging as important defects in childhood diseases as well as in cancer. The profiling technology described in this paper will help to uncover these epigenetic defects, providing biomarkers and leads for potential therapy.”





Related Links:
Cold Springs Harbor Laboratory
Orion Genomics

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.